- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14:42 | Pfizer's VYNDAQEL gets EC approval for treatment of ATTR-CM | ||
| 10:42 | Merck receives complete response letter from FDA for sBLAs for KEYTRUDA six-week dosing schedule | ||
| 09:42 | ALX Oncology's ALX148 receives two fast track designations from FDA | ||
| 08:42 | Audentes Therapeutics to build gene therapy manufacturing facility in North Carolina | ||
| Di | PharmaMar, Jazz get FDA priority review for lurbinectedin in relapsed SCLC | ||
| Di | FDA approves GSK's Voltaren Arthritis Pain for over-the-counter use in the US | ||
| Di | Ascletis' IND filing for its NASH drug accepted by NMPA | ||
| Di | Novartis gets EC nod for Beovu to treat wet AMD | ||
| Mo | Opdivo delivers superior five-year survival results in renal cell carcinoma | ||
| Mo | Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn's disease and ulcerative colitis | ||
| Mo | New phase 3b interim data from STARDUST study show majority patients with moderately to severely active Crohn's Disease achieved clinical remission after two doses of STELARA | ||
| Mo | Epizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma | ||
| Fr | Seattle Genetics gets FDA priority review for tucatinib in locally advanced or metastatic HER2-positive breast cancer | ||
| Fr | The US FDA accepts for priority review Bristol-Myers Squibb's BLA for liso-cel for adult patients with relapsed or refractory large B-cell lymphoma | ||
| Fr | Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC | ||
| Do | ALX Oncology announces closing of $105m Series C financing | ||
| Do | Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours | ||
| Do | Merck's Keytruda plus chemotherapy meets primary endpoint in mTNBC trial | ||
| 12.02. | Novartis' capmatinib gets FDA priority review in METex14 mutated advanced NSCLC | ||
| 12.02. | Dr. Reddy's Laboratories to acquire select business divisions of Wockhardt in India | ||
| 12.02. | Ligand agrees to acquire core assets, partnered programmes and ion channel technologies from Icagen | ||
| 12.02. | Pfizer, Astellas' Xtandi significantly improves OS in phase 3 prostate cancer study | ||
| 11.02. | Lilly's solanezumab fails to meet objective in phase 2/3 DIAN-TU Study | ||
| 11.02. | Moderna announces progress in prophylactic vaccines modality with CMV Vaccine phase 2 study data now expected in third quarter 2020 | ||
| 11.02. | Biohaven's troriluzole study for generalised anxiety disorder misses primary endpoint |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
